Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.96 |
| ▸ | MIF | P14174 | 13/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | GLA | P06280 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126040 | 0.98 | HSD17B3 (1.00) | HSD17B3MIFMEN1KMT2AKDM4E | |
| Bicarbonate SCHEMBL8425145 | 0.93 | HSD17B3 (0.90) | HSD17B3MIFMEN1KMT2AKDM4E | |
| Phosphoric Acid SCHEMBL6259521 | 0.92 | HSD17B3 (0.87) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL10791744 | 0.84 | HSD17B3 (0.74) | HSD17B3KDM4EGLAGAAESR2 | |
| SCHEMBL10852375 | 0.83 | HSD17B3 (0.71) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL11117135 | 0.81 | HSD17B3 (0.68) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL5296804 | 0.79 | HSD17B3 (0.68) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL890223 | 0.79 | HSD17B3 (0.68) | HSD17B3MIFCA9ALDH1A1HPGD | |
| SCHEMBL1368289 | 0.79 | MEN1 (0.76) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL220708 | 0.77 | HSD17B3 (0.65) | HSD17B3MIFMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689352-B1 | EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN | UNIV KAOHSIUNG MEDICAL (TW) | 2023-11-15 | — | — | EP | claimed |
| US-20210205450-A1 | METHOD FOR TREATING SUBJECT SUFFERING FROM FLAVIVIRUS INFECTION | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-07-08 | — | — | US | claimed |
| EP-3689352-A1 | EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN | Kaohsiung Medical University (TW) | 2020-08-05 | — | — | EP | claimed |
| US-20190107538-A1 | EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2019-04-11 | — | — | US | claimed |
| EP-3466426-A1 | EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN | Kaohsiung Medical University (TW) | 2019-04-10 | — | — | EP | claimed |
| EP-3689352-B1 | EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN | UNIV KAOHSIUNG MEDICAL (TW) | 2023-11-15 | — | — | EP | disclosed |
| US-11730811-B2 | Method for treating subject suffering from flavivirus infection | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2023-08-22 | — | — | US | disclosed |
| US-20210205450-A1 | METHOD FOR TREATING SUBJECT SUFFERING FROM FLAVIVIRUS INFECTION | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-07-08 | — | — | US | disclosed |
| EP-3466426-B1 | EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN | UNIV KAOHSIUNG MEDICAL (TW) | 2020-11-04 | — | — | EP | disclosed |
| CN-111521594-A | Novel nano-composite, preparation method thereof and application thereof in sewage detection | 重庆工程职业技术学院 | 2020-08-11 | — | — | CN | disclosed |
| EP-3689352-A1 | EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN | Kaohsiung Medical University (TW) | 2020-08-05 | — | — | EP | disclosed |
| EP-3689352-A1 | EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN | Kaohsiung Medical University (TW) | 2020-08-05 | — | — | EP | disclosed |
| US-20120136147-A1 | Method of hydrolyzing an enzymatic substrate | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-31 | — | — | US | disclosed |
| WO-2012062767-A2 | ENZYMES AND USES THEREOF | DEINOVE (FR) | 2012-05-18 | — | — | WO | disclosed |
| EP-1592786-B8 | DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER SULFATASE DEFICIENCIES USING A FORMYLGLYCINE GENERATING ENZYME (FGE) | SHIRE HUMAN GENETIC THERAPIES (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8093062-B2 | Enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-10 | — | — | US | disclosed |
| EP-1592786-B1 | DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER USING A FORMYLGLYCINE GENERATING ENZYME (FGE) | SHIRE HUMAN GENETIC THERAPIES (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-2325302-A1 | Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) | Shire Human Genetic Therapies, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2325301-A1 | Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) | Shire Human Genetic Therapies, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20110118132-A1 | Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil | ADVANCED LIQUID LOGIC, INC. (US) | 2011-05-19 | — | — | US | disclosed |